cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1171Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMCтарые принципы – новые горизонты в лечении ишемической болезни сердцаCoronary heart disease treatment: old principles and new horizonsВасюкЮ. А.VasyukYu. A.uji_98@yahoo.comШкольникЕ. Л.Shkol’nikE. L.uji_98@yahoo.comМосковский государственный медико-стоматологический университет, МоскваMoscow State Medico-Stomatological University, Moscow200720022007619298Copyright © Васюк Ю.А., Школьник Е.Л., 20072007Васюк Ю.А., Школьник Е.Л.Vasyuk Y.A., Shkol’nik E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1171

На основании литературных данных продемонстрирована связь между частотой сердечных сокращений (ЧСС) и смертностью при ишемической болезни сердца (ИБС) и артериальной гипертонии. Обоснована стратегия снижения ЧСС при ИБС как важная терапевтическая цель. Обсуждаются механизмы антиишемического и антиангинального действия принципиально нового препарата ивабрадина, специфически снижающего ЧСС за счет ингибиции ионных токов f-каналов синусового узла. Приведены клинические доказательства высокой эффективности препарата при стабильной стенокардии в сравнении с современными антиангинальными средствами; обсуждаются потенциальные преимущества его в клинических ситуациях, требующих снижения ЧСС.

Basing on literature data, the authors demonstrate the link between heart rate (HR) and mortality in coronary heart disease (CHD) and arterial hypertension. HR reduction strategy as an important therapeutic target in CHD management is proposed. Ant-ischemic and antianginal mechanisms of a novel agent, ivabradine, selectively reducing HR due to sinus node f-channel ion current inhibition, are discussed. Clinical evidence of ivabradine effectiveness in stable angina, comparing to other modern antianginal medications, is presented. Potential benefits of ivabradine therapy in HR reduction-requiring clinical situations are discussed.

стабильная стенокардияивабрадинIf-токиstable anginaivabradineIf-currentReferencesSigh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Therap 2001; 6: 313-31.Sigh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Therap 2001; 6: 313-31.Wilhelmsen L, Berlund G, Elmfeldt D, et al. The multifactor primary prevention trial in Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.Wilhelmsen L, Berlund G, Elmfeldt D, et al. The multifactor primary prevention trial in Geteborg, Sweden. Eur Heart J 1986; 7: 279-88.Шальнова С.В., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.Шальнова С.В., Деев А.Д., Оганов Р.Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.Beere P, Glagov S, Zarins C. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2.Zagotta WN, Olivier NB, Black KD, et al. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature 2003; 425: 200-5.Zagotta WN, Olivier NB, Black KD, et al. Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature 2003; 425: 200-5.Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparation: comparison with UL-FS49. Br J Pharmacol 1994; 112: 37-42.Thollon C, Cambarrat C, Vian J, et al. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparation: comparison with UL-FS49. Br J Pharmacol 1994; 112: 37-42.Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise induced myocardial ischemia in pigs. J Cardiovascular Pharmacol 2003; 42: 688-96.Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate reducing agent, in exercise induced myocardial ischemia in pigs. J Cardiovascular Pharmacol 2003; 42: 688-96.Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995; 275: 659-66.Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective lf current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective lf current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 2004; 109: 1674-9.Borer JD, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an lf inhibitor in stable angina. Circulation 2003; 107: 817-23.Borer JD, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an lf inhibitor in stable angina. Circulation 2003; 107: 817-23.Tardif J, Ford I, Tendera M, et al. On behalf of the INITIATIVE study investigators group. Antianginal and anti-ischemic effects of the lf current inhibitor ivabradine compared to athenolol as monotherapies in patients with chronic stable angina. Eur Heart J 2003; 24:Abstract 186.23.Tardif J, Ford I, Tendera M, et al. On behalf of the INITIATIVE study investigators group. Antianginal and anti-ischemic effects of the lf current inhibitor ivabradine compared to athenolol as monotherapies in patients with chronic stable angina. Eur Heart J 2003; 24:Abstract 186.23.Ruzyllo W, Ford I, Tendera M, et al. Antianginal and anti- ischemic effects of the lf current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2004; 25: Abstract 878.Ruzyllo W, Ford I, Tendera M, et al. Antianginal and anti- ischemic effects of the lf current inhibitor ivabradine compared to amlodipine as monotherapy in patients with chronic stable angina: A 3-month randomized, controlled, double-blind, multi-center trial. Eur Heart J 2004; 25: Abstract 878.Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25: Abstract 876.Lopez-Bescos L. Long-term safety and antianginal efficacy of the If current inhibitor ivabradine in patients with chronic stable angina. Eur Heart J 2004; 25: Abstract 876.Moosmang S, Steiber J, Zong W, et al. Cellular expression and functional characterization of four hyperpolarisation – activated pacemaker cannels in cardiac and neuronal tissues. Eur J Biochem 2001; 268: 1646-52.Moosmang S, Steiber J, Zong W, et al. Cellular expression and functional characterization of four hyperpolarisation – activated pacemaker cannels in cardiac and neuronal tissues. Eur J Biochem 2001; 268: 1646-52.

The authors declare that there are no conflicts of interest present.